🧪
hypothesis

Co-translational ER Targeting Defect and Lysosomal Delivery Failure

Hypothesis

Co-translational ER Targeting Defect and Lysosomal Delivery Failure

Retained introns contain upstream ORFs or alternative start sites producing N-terminal peptides that contain signal sequences directing co-translational ER targeting.
🧬 SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2)🎯 Composite 55%💱 $0.61▼1.2%proposed
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.66 (15%) Evidence 0.47 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.545 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite55%

🧪 Overview

Retained introns contain upstream ORFs or alternative start sites producing N-terminal peptides that contain signal sequences directing co-translational ER targeting. These aberrant peptides outcompete wild-type GBA nascent chains for SRP binding, preventing proper ER targeting of wild-type GBA. Without SRP-mediated targeting, wild-type GBA misfolds in the cytosol and is degraded by proteasome. Lysosomal delivery of residual GBA is impaired due to disrupted mannose-6-phosphate tagging. Importantly, LIMP-2 enhancement represents a therapeutic strategy independent of upstream mechanism validation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["SRP54/SRP68/SRP72<br/>Signal Recognition Particle"]
    B["Co-Translational<br/>ER Targeting Defect"]
    C["SCARB2 (LIMP2)<br/>Lysosomal Targeting"]
    D["Lysosomal<br/>Proteostasis Failure"]
    E["Proteostatic<br/>Stress"]
    F["ER<br/>Associated Degradation"]
    G["Neurodegeneration<br/>Protein Misfolding"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
Aberrant translation initiation blocks SRP recruitment to normal transcripts
PMID:31171707
Supports
LIMP-2 mediates GBA lysosomal targeting
PMID:17897319
Supports
Co-translational targeting defects cause ER mistargeting in neurodegeneration
PMID:35212470
Supports
LIMP-2 enhancement is a clean therapeutic target (enhancement, not inhibition)
PMID:30704899
Contradicts
SRP modulation would affect all secretory proteins including insulin and cytokines
PMID:30834756
Contradicts
No validated screening assays for LIMP-2 enhancers currently exist
PMID:31785729
Contradicts
Mechanistic prediction (aberrant peptide production) not directly demonstrated for GBA introns
PMID:33741742
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SRP54

No curated PDB or AlphaFold mapping for SRP54 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2) from GTEx v10.

Cerebellar Hemisphere32.9 Spinal cord cervical c-129.8 Cerebellum27.2 Hypothalamus26.2 Frontal Cortex BA924.1 Nucleus accumbens basal ganglia20.7 Substantia nigra19.2 Caudate basal ganglia18.7 Cortex18.5 Anterior cingulate cortex BA2418.1 Hippocampus16.5 Amygdala16.4 Putamen basal ganglia16.1median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2) →

No DepMap CRISPR Chronos data found for SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0721
Events (7d)
1
Price History
▼1.2%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we achieve >2-fold overexpression of LIMP-2 (SCARB2) via lentiviral transduction in iPSC-derived neurons from GBA-associated Parkinson's disease patients, THEN lysosomal GBA activity (4-MUG hydrolyIncreased lysosomal GBA enzymatic activity (fluorometric assay) and increased lysosomal GBA protein (by immunoprecipitation-Western blot with mannose-6-phosphat— no observation —pending0.60
IF we overexpress an N-terminal signal peptide-encoding ORF from a GBA retained intron in HEK293T cells, THEN wild-type GBA protein levels in ER-enriched fractions will decrease by >40% and cytosolic Decreased ER-localized wild-type GBA (Western blot signal reduction) and increased proteasome-degraded GBA (K48-linked ubiquitin co-immunoprecipitation)— no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we overexpress an N-terminal signal peptide-encoding ORF from a GBA retained intron in HEK293T cells, THEN wild-type GBA protein levels in ER-enriched fractions will decrease by >40% and cytosolic ubiquitinated GBA will increase by >50%, within 72 hours of transfection.
Predicted outcome: Decreased ER-localized wild-type GBA (Western blot signal reduction) and increased proteasome-degraded GBA (K48-linked ubiquitin co-immunoprecipitatio
Falsification: Wild-type GBA ER fraction remains within 10% of baseline despite aberrant peptide overexpression at levels sufficient to alter SRP availability (confirmed by SRP54 co-IP)
pendingconf 60%
IF we achieve >2-fold overexpression of LIMP-2 (SCARB2) via lentiviral transduction in iPSC-derived neurons from GBA-associated Parkinson's disease patients, THEN lysosomal GBA activity (4-MUG hydrolysis) will increase by >30% and lysosomal GBA protein will increase by >40% compared to empty vector
Predicted outcome: Increased lysosomal GBA enzymatic activity (fluorometric assay) and increased lysosomal GBA protein (by immunoprecipitation-Western blot with mannose-
Falsification: Lysosomal GBA activity remains within 15% of empty vector baseline despite confirmed LIMP-2 overexpression and normal LIMP-2 trafficking to lysosomes (LIMP-2:lysosomal marker colocalization >70%)
View on SciDEX ↗